ENHANCING ADVERSE PATHOLOGY PREDICTION IN ACTIVE SURVEILLANCE CANDIDATES: THE ADDED VALUE OF ONCOTYPE DX GENOMIC PROSTATE SCORE BEYOND MRI AND PSA DENSITY

Author(s)

• 

  Yu Ozawa, MD

  CLINICAL FELLOW
  ADVENTHEALTH GRI
  Celebration, Florida, United States
• MS

  Marco Sandori, n/a

  Staff
  University of Brescia, United States
• RS

  Rohan Sharma, n/a

  Senior Clinical Fellow
  AdventHealth Global Robotics Institute, United States
• 

  Marcio Covas Moschovas, MD, PhD

  Core Faculty
  AdventHealth Celebration
  kissimee, Florida, United States
• SS

  SHADY SAIKALI, MD

  CLINICAL FELLOW
  ADVENTHEALTH GRI, United States
• TR

  Travis Rogers, n/a

  Robotic Surgeon
  AdventHealth Global Robotics Institute, United States
• 

  Vipul R. Patel, MD

  Urology department and robotic Surgery
  AdventHealth Global Robotics Institute, Florida, United States